[Company claims products]… intended to deliver compounds across the blood-brain-barrier while bypassing the GI tract and liver, eliminating hallucinogenic effects… ability to precisely manufacture compounds different size, different shape, different delivery mechanisms… and immense advantage compared to any competitor in the field…
“I enjoyed visiting Psycheceutical’s lab and meeting some of the team behind the NeuroDirect ketamine cream. I’ve been working in psychedelics for more than 40 years, and it’s rare for me to come across something unique like the NeuroDirect topical cream that is currently being developed by Psycheceutical with the goal of delivering a psychedelic compound without a psychedelic experience or negative side effects. Our approach to PTSD at MAPS are macrodoses of MDMA for three eight-hour sessions – large cathartic experiences for extended periods of time – embedded in a series of twelve 90 minute non-drug psychotherapy sessions for preparation and integration. I could see the possibility of NeuroDirect ketamine being helpful during the integration therapy, for example,” said Rick Doblin.
Original Article (Global Newswire & Yahoo & Psycheceutical):
Psycheceutical hosts MAPS founder and psychedelic industry leader Rick Doblin at its drug development lab & Psycheceutical Hosts MAPS founder and psychedelic industry leader Rick Doblin at its drug development lab & Psycheceutical
Artwork Fair Use: Robyn Lisa Butt and Helene Volkoff